UPDATE: Trump Signs Executive Order to Reschedule Cannabis and Expand Federal Policy - Foley Hoag
President Trump signed an executive order to reschedule cannabis under the Controlled Substances Act, moving it from Schedule I to a lower schedule, and expanding federal policy on cannabis. This change affects DEA quotas, research protocols, and compliance requirements for pharmaceutical manufacturers handling controlled substances.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 22, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing facilities (503B) that handle or plan to handle cannabis-derived or cannabis-related controlled substances. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; executive order takes effect upon signing, but formal rulemaking may follow. Monitor DEA guidance within 30 days.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Cannabis is rescheduled from Schedule I to a lower schedule (likely Schedule II or III), altering DEA quota allocations, registration requirements, and manufacturing controls under the Controlled Substances Act.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing facilities (503B) that handle or plan to handle cannabis-derived or cannabis-related controlled substances.
What you must do
Review and update DEA registrations, quota applications, and security/storage protocols to align with new scheduling; assess impact on existing drug development programs and supply chains.
Deadline
Immediately; executive order takes effect upon signing, but formal rulemaking may follow. Monitor DEA guidance within 30 days.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- US-CONGRESS BILLS-119hr2821eh: FDA Modernization Act 3.0
- US-CONGRESS BILLS-119hr9599ih: Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act; SECURE 340B Act
- US-CONGRESS S1041: Affordable Prescriptions for Patients Act
- Determination That RASUVO (Methotrexate) Solution, 27.5 Milligrams/0.55 Milliliter (27.5 Milligrams/0.55 Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- US-CONGRESS BILLS-119hr9774ih: To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes.